<div id="readability-page-1"><p>Frazier Life Sciences Management L.P. boosted its holdings in shares of  Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 19.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 625,000 shares of the biotechnology company's stock after acquiring an additional 100,000 shares during the quarter. Frazier Life Sciences Management L.P. owned 0.49% of Avidity Biosciences worth $17,750,000 at the end of the most recent quarter.</p><ul><li>This Early-Stage Biotech Stock Is Up 400% — Should You Buy Now?</li></ul><p>Several other large investors have also recently modified their holdings of the business. Wellington Management Group LLP grew its stake in shares of  Avidity Biosciences by 19.5% in the first quarter. Wellington Management Group LLP now owns 9,684,556 shares of the biotechnology company's stock worth $285,888,000 after purchasing an additional 1,578,459 shares during the last quarter.  Norges Bank bought a new position in  Avidity Biosciences during the 2nd quarter worth $28,261,000.  T. Rowe Price Investment Management Inc. acquired a new position in  Avidity Biosciences during the 1st quarter worth about $22,765,000.  Nuveen LLC bought a new stake in shares of  Avidity Biosciences in the 1st quarter valued at about $12,729,000.  Finally, Price T Rowe Associates Inc. MD increased its stake in shares of  Avidity Biosciences by 2.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 11,338,098 shares of the biotechnology company's stock valued at $334,701,000 after buying an additional 295,275 shares during the period. </p><div><p><span></span><span>Get <strong>Avidity Biosciences</strong> alerts:</span></p></div><h2>Insider Buying and Selling at Avidity Biosciences</h2><p>In related news, insider Steven George Hughes sold 2,209 shares of Avidity Biosciences stock in a transaction on Wednesday, October 22nd. The shares were sold at an average price of $47.54, for a total value of $105,015.86. Following the completion of the sale, the insider owned 38,867 shares of the company's stock, valued at approximately $1,847,737.18. This trade represents a 5.38% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Teresa Mccarthy sold 20,000 shares of the business's stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $50.15, for a total transaction of $1,003,000.00. Following the sale, the insider owned 97,130 shares of the company's stock, valued at $4,871,069.50. This trade represents a 17.08% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 30,979 shares of company stock valued at $1,495,400. Company insiders own  3.83% of the company's stock. </p><h2>Analyst Ratings Changes</h2><p>RNA has been the topic of a number of recent analyst reports. Wall Street Zen raised Avidity Biosciences from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Saturday, October 25th. Loop Capital  set a $72.00 price target on shares of Avidity Biosciences in a report on Tuesday, October 28th. Chardan Capital  restated a &#34;neutral&#34; rating and issued a $72.00 price target on shares of Avidity Biosciences in a research report on Tuesday, November 11th. Bank of America increased their price objective on shares of Avidity Biosciences from $56.00 to $65.00 and gave the stock a &#34;buy&#34; rating in a research report on Monday, September 15th. Finally, Citigroup downgraded shares of Avidity Biosciences from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Monday, October 27th. Nine research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one  has assigned  a Sell rating to the company's stock. According to MarketBeat, the company  has a consensus rating of &#34;Hold&#34; and a consensus price target of $69.24.</p><p><b>Check Out Our Latest Stock Report on RNA</b></p><h2>Avidity Biosciences Trading Up 0.3%</h2><p>Shares of NASDAQ RNA opened at $71.83 on Friday. The firm has a market capitalization of $10.82 billion, a P/E ratio of -17.18 and a beta of 0.90. The firm's 50-day moving average price is $64.10 and its 200-day moving average price is $47.12. Avidity Biosciences, Inc. has a 1-year low of $21.51 and a 1-year high of $71.88. </p><p>Avidity Biosciences (NASDAQ:RNA - Get Free Report) last issued its earnings results on Monday, November 10th. The biotechnology company reported ($1.27) EPS for the quarter, missing the consensus estimate of ($1.05) by ($0.22). Avidity Biosciences had a negative net margin of 2,634.59% and a negative return on equity of 37.70%. The firm had revenue of $12.48 million during the quarter, compared to analyst estimates of $1.80 million. The business's revenue was up 420.8% on a year-over-year basis.  Equities research analysts forecast that  Avidity Biosciences, Inc. will post -2.89 EPS for the current year. </p><h2>Avidity Biosciences Profile</h2> (Free Report)<p>Avidity Biosciences, Inc, a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Avidity Biosciences</li><li>Special Purpose Acquisition Company (SPAC) What You Need to Know </li><li>Synopsys Sees Bullish Shift as Ansys Integration Drives Growth</li><li>Stock Ratings and Recommendations: Understanding Analyst Ratings</li><li>The Best Holiday Present You Can Give Yourself? Costco Stock</li><li>Following Congress Stock Trades</li><li>Why Zscaler Stock Could Be Ready to Bounce After a 30% Selloff</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Uk5B?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Uk5B"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Avidity Biosciences Right Now?</h2><p>Before you consider Avidity Biosciences, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avidity Biosciences wasn't on the list.</p><p>While Avidity Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Frazier Life Sciences Management L.P. increased its stake in Avidity Biosciences by 19% in Q2, owning 625,000 shares valued at $17.75 million. Other investors like Wellington Management and Norges Bank also modified their holdings. Insider trading saw significant sales by company insiders. Analysts have mixed ratings on Avidity Biosciences, with a consensus 'Hold' rating and a price target of $69.24. The stock is trading at $71.83, with a market cap of $10.82 billion.</p>

Frazier Life Sciences Management L.P. Has $17.75 Million Stock Holdings in Avidity Biosciences, Inc. $RNA